

Approved through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	<b>09/936,957</b>
<b>Filing Date</b>	<b>September 17, 2001</b>
<b>First Named Inventor</b>	<b>Meikle</b>
<b>Group Art Unit</b>	<b>Unassigned</b>
<b>Examiner Name</b>	<b>Unassigned</b>
<b>Attorney Docket Number</b>	<b>021385-014010US</b>

*(use as many sheets as necessary)*

Sheet	1	of	3
-------	---	----	---

[illegible][illegible]

Examiner Signature		Date Considered	3/17/08
-----------------------	---	--------------------	---------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

PA 3224427 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	09/936,957
Filing Date	September 17, 2001
First Named Inventor	Meikle
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	021385-014010US

Sheet 2 of 3

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AB	AB	AERTS et al., "The occurrence of two immunologically distinguishable $\beta$ -glucocerebrosidases in human spleen," <u>Eur. J. Biochem.</u> , 150:565-574 (1985).	
AC	AC	BAGHDIGUIAN et al., "Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells," <u>Cancer Letters</u> , 101:179-184 (1996).	
AD	AD	BURKHARDT et al., "The Giant Organelles in Beige and Chediak-Higashi Fibroblasts Are Derived from Late Endosomes and Mature Lysosomes," <u>J. Exp. Med.</u> , 178:1845-1856 (1993).	
AE	AE	CHAMBERLAIN et al., "Generation and Characterization of Monoclonal Antibodies to Human Type-5 Tartrate-Resistant Acid Phosphatase: Development of a Specific Immunoassay of the Isoenzyme in Serum," <u>Clin. Chem.</u> , 41(10):1495-1499 (1995).	
AF	AF	COLMAN, P., "Effects of amino acid sequence changes on antibody-antigen interactions," <u>Research In Immunology</u> , 145:33-36 (1994).	
AG	AG	CONARY et al., "Synthesis and Stability of Steroid Sulfatase in Fibroblasts from Multiple Sulfatase Deficiency," <u>Biological Chemistry</u> , 369:297-302 (1988).	
AH	AH	DAHLGREN et al., "The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in mobilizable organelles, but are absent from the azurophilic granules of human neutrophils," <u>J. Biochem.</u> , 311:667-674 (1995).	
AI	AI	KARAGEORGOS et al., "Lysosomal Biogenesis in Lysosomal Storage Disorders," <u>Experimental Cell Research</u> , 234:85-97 (1997).	
AJ	AJ	KISHIMOTO et al., "Saposins: structure, function, distribution, and molecular genetics," <u>J. Lipid Research</u> , 33:1255-1267 (1992).	
AK	AK	MEIKLE et al., "Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker," <u>Clinical Chemistry</u> , 43(8):1325-1335 (1997).	
AL	AL	MICHELAKAKIS et al., "Characterization of glucocerebrosidase in Greek Gaucher disease patients: mutation analysis and biochemical studies," <u>J. Inher. Metab. Dis.</u> , 18:609-615 (1995), with abstract	
AM	AM	PASCHKE et al., "Infantile type of sialic acid storage disease with sialuria," <u>Clinical Genetics</u> , 29:417-424 (1986).	
AN	AN	RENLUND, M., "Clinical and laboratory diagnosis of Salla disease in infancy and childhood," <u>Journal of Pediatrics</u> , 104(2):232-236 (1979).	
AO	AO	RENLUND et al., "Increased Urinary Excretion of Free N-Acetylneuraminic Acid in Thirteen Patients with Salla Disease," <u>European Journal of Biochemistry</u> , 101:245-250 (1979).	
AP	AP	RENLUND et al., "Salla disease: A new lysosomal storage disorder with disturbed sialic acid metabolism," <u>Neurology</u> , 33:57-66 (1983).	


Examiner Signature		Date Considered	3/17/08
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3224427 v1

Please type a plus sign (+) inside this box →



Approved through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/936,957
		Filing Date	September 17, 2001
		First Named Inventor	Meikle
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 3 of 3	Attorney Docket Number	021385-014010US	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AA	AQ	RENLUND et al., "Studies on the Defect Underlying the Lysosomal Storage of Sialic Acid in Salia Disease: Lysosomal Accumulation of Sialic Acid Formed From N-Acetyl-Mannosamine or Derived from Low Density Lipoprotein in Cultured Mutant Fibroblasts," <u>Journal of Clinical Investigation</u> , 77:568-574 (1986).	
AA	AR	RODRIGUEZ-SERNA et al., "Angiokeratoma Corporis Diffusum Associated With $\beta$ -Mannosidase Deficiency," <u>Arch. Dermatol.</u> , 132:1219-1222 (1996).	
AA	AS	SANDOVAL et al., "Lysosomal Integral Membrane Glycoproteins Are Expressed at high Levels in the Inclusion Bodies of I-Cell Disease Fibroblasts," <u>Arch. Biochem. &amp; Biophysics</u> 271(1):157-167 (1989).	
AA	AT	WAHEED et al., "Enhanced Breakdown of Arylsulfatase A in Multiple Sulfatase Deficiency," <u>European Journal of Biochemistry</u> , 123:317-321 (1982).	

Examiner Signature		Date Considered	3/17/08
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3224427 v1